|
**Overview**: FISH 14q32-3 IGH Panel**Introduction**: The FISH 14q32-3 IGH Panel is a diagnostic tool designed to detect IGH gene rearrangements using whole blood or bone marrow samples. In India, IGH translocations (e.g., t(14;18) in follicular lymphoma, t(14;16) in multiple myeloma) occur in ~10-20 percent of B-cell malignancies, guiding prognosis and targeted therapy (e.g., bortezomib in myeloma with IGH abnormalities). High morbidity from under-testing in rural/low-SES hematology patients, limited FISH access, delayed risk-adapted treatment leading to progression. Per cytogenetics practices aligned with ICMR and Indian Society of Hematology guidelines, the test employs FISH for IGH breakapart over 1-2 days with high sensitivity/specificity, valuable for molecular subtyping in lymphoma/myeloma. This diagnostic falls under genetic cancer screening and targets patients with B-cell malignancies, addressing accurate detection to guide therapy and prognosis. With elevated morbidity due to under-testing, the test supports public health efforts by enabling precise genetic classification and improving outcomes. Its blood/bone marrow-based approach ensures reliable rearrangement detection.**Other Names**: FISH IGH Pnl.**FDA Status**: FDA approved, CLIA certified for cytogenetics, compliant with 2025 standards.**Historical Milestone**: IGH FISH standard; in India, used in lymphoma/myeloma protocols.**Purpose**: The test detects 2 parameters including IGH gene breakapart to guide genetic assessment, identify translocations, inform therapy/prognosis.**Test Parameters**: 1. IGH Gene Breakapart, 2. Chromosomal Rearrangement.**Pretest Condition**: No fasting required; patients should have confirmed B-cell malignancy.**Specimen**: 3 mL whole blood or bone marrow in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve cell viability, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for FISH).**Medical History**: Patients should provide details on malignancy subtype, stage, prior therapy.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undetected IGH rearrangement including poor prognosis, benefits of detection, and minimal discomfort from blood/bone marrow draw.**Procedural Considerations**: The test involves sample processing using FISH by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided probes/controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low tumor burden can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive IGH rearrangement indicates specific subtype, necessitating specialist input. Negative may require follow-up.**Specialist Consultation**: Hematologists/oncologists should be consulted for management.**Additional Supporting Tests**: Karyotype, NGS for confirmation.**Test Limitations**: Detects rearrangement only; comprehensive approach required.**References**: Indian Journal of Hematology 2024, Lymphoma Studies India 2023. |
